Complication Of Lymphoma Research Articles

Complications of lymphoma in the abdomen and pelvis: clinical and imaging review.

Involvement of the abdomen and pelvis is common in lymphoma. Nodal and extranodal abdominal and pelvic lymphoma may present with various complications. Complications are most common in high-grade lymphomas, especially diffuse large B-cell lymphoma. Complications may occur as the initial manifestation of lymphoma, during treatment course, or late following complete disease remission. Most complications are associated with worse prognosis and increased mortality. Imaging is essential in evaluation of disease extent and diagnosis of complications. Therefore, radiologists should be familiar with the clinical context and imaging features of abdominal and pelvic lymphoma complications. We provide a comprehensive, organ system-based approach, and clinical and imaging review of complications of abdominal and pelvic lymphoma along with radiologic images of illustrated cases of the most commonly encountered complications.

Perforation of the colon, diffuse septic fibrinous peritonitis in a patient with diffuse large B-cell lymphoma. Clinical observation

Perforation of a hollow organ with development of peritonitis is a known complication of lymphomas often occurring during diagnosis or therapy. Frequency of perforations of the gastrointestinal tract in patients with lymphomas is 9 %. Presence of a perforation complicates treatment and can worsen disease prognosis. A clinical case of a patient with diffuse large B-cell lymphoma complicated by surgical pathology and infection is presented: perforation of the transverse colon, fibrinous septic peritonitis were detected during a diagnostic procedure (prior to morphological verification of the diagnosis), and COVID-associated pneumonia developed later. The selected treatment tactics despite the volume of surgical intervention and presence of infectious complications allowed to achieve improvement of the patient’s condition.

Gastro-Splenic Fistula from Diffuse Large B-Cell Lymphoma: Case Report

A gastro-splenic fistula is a rare complication of lymphoma, the etiology of which is poorly understood due to the narrow spectrum of cases. Additional case reports of this complication allow for increased understanding to facilitate treatment planning. This case report provides our detailed patient scenario and surgical approach to a gastro-splenic fistula in the setting of large B-cell lymphoma and compares this approach to similar cases provided in the literature review

Signs, Symptoms and Complications of Non-Hodgkin's Lymphoma According to Grade and Stage in South Iran.

Non-Hodgkin's lymphoma (NHL) is a heterogeneous type of neoplasm of the lymphatic system. To have a more accurate and early diagnosis we need to know signs, symptoms and complications of lymphoma in early stages besides pathology and immunohistochemistry. This prospective study included 110 cases of NHL that were followed since February 2012 till November 2013. Biopsies were taken from all the patients besides bone marrow study. Signs and symptoms were categorized into "B" symptoms, general, lymphadenopathy and extranodal involvement and we compared the frequencies by stage and grade. Of 110 cases, 88.9% had B-cell and 11.1% T-cell type with mean age 48.5±18.6 years. "B" symptoms and lymphadenopathy were more common in men. Cervical lymphadenopathy was the most common sign (44.8%). and hematologic, bone marrow, bone and neurologic lesions were the most common complications. All complications were more common in males. "B" symptoms were seen mostly in stage III, general signs and symptoms in stage IV, and lymphadenopathy in stage II. Intermediate grade was also the most common in all signs and symptoms. In this study 12 (10.9%) patients had relapse, with neurologic and bone marrow as the most common sites of tumor recurrence. There is a meaningful relationship between male gender for NHL and anemia that can be due in part to higher incidence of bone marrow involvement and stage IV disease in male cases. We also found a strong relationship between low grade NHL and age. On the other hand extranodal involvement is more common in female groups.

Follicular Lymphoma Patient Relapsing with Paraneoplastic Sensory Neuronopathy (Ganglioneuropathy)

Neurological symptoms can be seen in 5%-8% of lymphoma patients. The most frequent causes of neurological symptoms are herpes virus infection, neurotoxicity due to vincristine, Guillain–Barre syndrome, and the nerve involvement of the tumor [1]. Paraneoplastic polyneuropathy is a rare neurological complication of lymphoma [2]. Here we report a case of relapsed follicular lymphoma presenting with paraneoplastic sensory neuropathy (ganglioneuropathy). A 45-year-old woman was admitted to the hospital 2 years ago with the complaints of numbness in the hands and feet, unsteadiness, weight loss, fever, and swellings in the neck, axilla, and inguinal region. She was diagnosed with follicular lymphoma through the excisional biopsy of the cervical lymph node. She was diagnosed with stage 3B disease based on the presence of lymphadenopathies in the paratracheal, precarinal, axillary, and inguinal regions and no infiltration by bone marrow examination. The treatment started with rituximab (500 mg/day), cyclophosphamide (1125 mg/day), adriablastine (80 mg/day), vincristine (2 mg/day), and prednisolone (80 mg/day). Therapy was completed in 8 courses with 21-day intervals. After the therapy, all of the symptoms had regressed and the case was evaluated as in remission with a follow-up PET scan (Figure 1). Gradually increasing unsteadiness, numbness, and pain and burning sensation in the hands and feet developed 1 month following that PET study. She applied to the neurology service and it was found that she had normal muscle strength but mild ataxia, positive Romberg test, and prominent hypoesthesia in the distal regions of the extremities and bilateral impairment of the deep tendon reflexes and indifferent plantar responses. Informed consent was obtained. An electromyography revealed sensorial gangliopathy. On physical examination the positioning and the vibration sensations of the patient were found to be diminished. Intravenous pulse steroid therapy (1000 mg/day) was administered for 5 days. Two days after this therapy, a severe and generalized pain developed in all of the extremities and joints. In neurological examination, distinct quadriparesis, ataxia, dysmetria, dysdiadochokinesia, hypoesthesia of the 4 extremities, and bilateral abolished deep tendon reflex with indifferent plantar responses were determined. There was Letter to the Editor DOI: 10.4274/TJH-2013.0125

An aggressive form of non-Hodgkin's lymphoma with pleural and abdominal chylous effusions: A case report and review of the literature

Serous effusions, including pleural, abdominal and pericardial effusions, are complications of lymphoma. Among these types, pleural effusions are the most common to be observed. However, the involvement of the abdominal or pericardial cavity is rare. An impairment of the lymphatic drainage and direct infiltration have been identified to play significant roles in effusion formation. Multiple techniques, including cytological exams, immunochemistry and cytogenetics, have been applied in the clinic to access the qualities of the effusions and to attain a fast and precise diagnosis. Serous effusions are associated with a poor outcome for patients with lymphoma. The present study describes the case of a 28-year-old male patient with aggressive non-Hodgkin's lymphoma (NHL) involving pleural and abdominal chylous effusions.

Hemophagocytic Lymphohistiocytosis Complicating T-Cell Lymphoma in a Patient with HIV Infection

Hemophagocytic lymphohistiocytosis (HLH), while uncommon, may be a devastating complication of lymphoma and/or human immunodeficiency virus (HIV) infection. While several of the diagnostic criteria for HLH are relatively nonspecific, particularly in the setting of a systemic inflammatory response, more diagnostic specificity may be achieved with marked elevations in serum ferritin (e.g., >100,000 ng/mL). Increased suspicion of HLH, particularly in the setting of persistent, unexplained fevers, pancytopenia, and transaminitis, should prompt consideration of HLH. Earlier diagnosis and initiation of therapy have the potential to alter the natural history and poor prognosis of this disorder. We present a patient with HIV infection who developed relapsed T-cell lymphoma complicated by hemophagocytic lymphohistiocytosis.

A case of non-Hodgkin's lymphoma presented with tension chylothorax

We present an unusual case of diffuse large B-cell lymphoma which initially presented as tension chylothorax. A 24-yearold man was admitted to our clinic with the complaints of dyspnea, fever, and sweating. Chest X-ray revealed a massive right pleural effusion. The patient was diagnosed with chylothorax and a right tube thoracostomy was performed. Thorax computed tomography revealed parenchymal infiltration in the right lower lobe, right hydropneumothorax, and multiple paratracheal lymphadenopathies. The general status of the patient was poor, and the submandibular lymph node was excised for pathological diagnosis. The general status of the patient gradually got worse and on the 13th day of the admission, intubation and mechanical ventilation were instituted. The pathological diagnosis of the lymph node was reported as diffuse large B-cell lymphoma, and the patient died only two days after the histopathological diagnosis. Chylothorax may arise as a complication of lymphoma. While, there are no reports on the frequency of this occurrence, it is associated with a high mortality rate when the patient presents with tension chylothorax.

Risk of Second Malignant Neoplasm Among Patients With Lymphoma

TO THE EDITOR: The recently published article, “Long-Term Complications of Lymphoma and Its Treatment,” by Ng et al 1 provides a much needed overview of its topic. Unfortunately, however, the article fails to emphasize two key concepts: first, the necessity of investigating the impact of associated rituximab treatment in nonHodgkin’s lymphoma on long-term complications, and second, the differences in risk of a new, second malignancy caused by a lymphoma subtype. Briefly, the monoclonal antibody rituximab has increased disease-free survival for many lymphoid malignant diseases and seems not to have a significant influence on secondary myelodysplastic syndromes/acute myeloid leukemia, whereas it has emerged as an independent risk factor for solid tumor development. 2 In addition, even if the precise role played by B cells in cancer biology remains to be defined, recent reports stress antitumor B-cell— derived immunity. 3,4 In other words, it seems conceivable that the profound immunosuppression that is secondary to B-cell deletion by rituximab may contribute to the expansion of tumor cells. Given that the occurrences of lung cancer and melanoma are limited to more indolent lymphomas, it is plausible that long-term immune dysfunction from the underlying disease or repeated treatments is responsible. Furthermore, the heightened risks immediately after chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and follicular lymphoma (FL) diagnoses suggest an intrinsic mechanism, possibly involving prediagnostic immune alterations or defects in a cell cycle and apoptosis, which are more characteristic of indolent rather than aggressive lymphomas. Recent findings demonstrate substantial heterogeneity in the occurrence of a second malignancy by a lymphoma subtype, which suggests differences in etiology. Specifically, significantly different patterns of second malignancy after CLL/SLL, diffuse large B-cell lymphoma (DLBCL), and FL among patients without HIV/AIDS-related lymphoma have been reported. 5 Most notable were the elevated risks for lung cancer and melanoma after the more indolent lymphomas, but not after the more aggressive DLBCL. Furthermore, survivors of CLL/SLL and FL have demonstrated a greater risk of developing other nonhematologic malignancies (ie, salivary gland, colon, anus, and thyroid), whereas, in contrast, no evidence has been reported, to our

Immunoglobulin G4-related chronic sclerosing dacryoadenitis

A 47-year-old man had recurrent, episodic swelling of the right upper eyelid for about 2 years. There was a progressively enlarging, palpable mass over the superotemporal region of the right orbit without tenderness, local heat, or erythema. Ophthalmic examination revealed proptosis and ptosis of the right eye without vision decrease or ocular motility disturbance. An orbital computed tomography scan showed a huge lacrimal gland causing inferior displacement of the globe with proptosis. An anterior orbitotomy was done, and the pathological analysis revealed marked lymphoplasma cell infiltration with mild to moderate fibrosis surrounding the lobules of the lacrimal glands. No lymphoepithelial islands were seen. Immunohistochemically, about 40–50% of the immunoglobulin G (IgG)-positive cells were IgG4 positive, and the ratio of serum IgG4 to total IgG was 80.9%, compatible with a diagnosis of IgG4-related chronic sclerosing dacryoadenitis. IgG4-related chronic sclerosing dacryoadenitis may be a sign of Mikulicz disease, an IgG4-related systemic disease. Determination of the serum IgG4 concentration and IgG4/IgG ratio is necessary for clinical diagnosis. Long-term follow-up is also mandatory because of the possible complication of lymphoma.

Introduction: Remembering Phil

This issue of the Journal of the History of Biology is dedicated to the memory of Philip Joseph Pauly, who died from complications of lymphoma on April 2, 2008, at the age of 57. Phil was a professor in the History Department at Rutgers University, where he had been a faculty member since 1981. In this collection of reminiscences and articles we wish to honor him as a scholar, colleague, friend, mentor to students, and supporter of our discipline. The essays following the reminiscences reflect in various ways on the ideas in Phil’s three books and related articles. Their themes reveal the diverse directions in which Phil’s ideas could be taken, showing how his work inspired and challenged us on many fronts. His revised dissertation on Jacques Loeb, completed in 1981 at the Johns Hopkins University, was published in 1987 as Controlling Life: Jacques Loeb and the Engineering Ideal in Biology. There followed a superbly crafted and insightful study of American biology, with emphasis on the Progressive Era, Biologists and the Promise of American Life; from Meriwether Lewis to Alfred Kinsey, published in 2000. Phil’s third book, Fruits and Plains: The Horticultural Transformation of America (2007) developed the themes of the second book but explored in a bolder way a synthetic history that aimed to ‘‘see the past as a whole’’ by combining histories of the environment,

Editor's Comment

This is the last Editor’s Comment of the year and under usual circumstances it would recount the events of 2008 relating to the Journal, recounting the changes and innovations which have taken place, and many other issues. Unfortunately, as I look back over the year, all of my happiness about the Journal is clouded by the deaths of three of our urological colleagues; urological oncology in particular has been hit hard by their passing. In April, John Stein died suddenly while attending the annual meeting of the American Association of Genitourinary Surgeons. This totally tragic event dominated our thoughts thereafter and led to many tributes in the urological literature. I wrote about my personal feelings at the loss, in my Editor’s comment in the August issue of the BJU International. The special issue, which we published in November on bladder cancer, edited by Seth Lerner and Cora Sernberg, was dedicated to the memory of John Stein, and contained a wonderful tribute by Don Skinner. It is still hard to believe that one so young is no longer with us and we very much miss his erudite presence. In September, a further loss occurred. John Donohue, in many ways the father of the modern management of testicular cancer, died suddenly in Florida. His contribution was monumental and his wisdom great. He gave advice on cases in a most helpful way and his company was something that I always particularly enjoyed. He will be very much missed by a huge band of admirers. It was a sad irony that I was informed of his death by his long-time associate, Larry Einhorn, who was our guest in Dublin at that time. I was particularly saddened by the loss of Andy Novick in October. He has been a great friend for many years, for as long as I can remember. He died from complications of lymphoma and it is a measure of the man that although I was very close to him, I did not know he was ill. His dedication to renal and adrenal surgery continued unabated until his final days, where his inner strength allowed him to maintain his professional duties. I feel a deep personal loss that Andy is no longer with us. He was a giant in the field of urological oncology. I hope that the readers of the BJU International have a relaxed festive season, and as usual I extend my heartfelt thanks to all concerned with the production of the Journal, particularly Audraí O’Dwyer, the Managing Editor and her assistants Karen Somers and Geraldine O’Shea. I would also like to thank the Associate Editors and the reviewers for their outstanding help over the last year.

Type B Lactic Acidosis As a Severe Metabolic Complication in Lymphoma and Leukemia

Type B lactic acidosis is a rare complication of hematologic malignancies. The exact mechanism of this process is not well understood. Because caregivers may not be aware of the association of type B lactic acidosis with hematologic malignancies, it may go unrecognized as a cause of acidosis in these patients. We report the cases of 7 patients with type B lactic acidosis who were cared for by members of the Brown Medical School Hematology/Oncology Division. Of the 7 patients reported, 5 had lymphomas and 2 had chronic lymphocytic leukemia. One of the lymphomas was a T-cell lymphoma. Of the patients we were able to evaluate, there did not seem to be a unique cluster of differentiation marker in association with type B lactic acidosis. We also review 14 additional cases, most reported since 2001. From our review of the literature, we suggest that a deficiency of thiamine or riboflavin may play a more pivotal role than previously recognized in the development of type B lactic acidosis associated with malignancy. Further investigation should be undertaken to learn if thiamine or riboflavin replacement might be useful in treating this disorder.

Peter Kellaway, PhD (1920–2003)

Peter Kellaway, renowned neurophysiologist and epileptologist, died June 25, 2003 in Houston, Texas, from complications of lymphoma, a disorder that he had battled for more than a decade. He was 82-years-old and had worked actively until his death. Dr. Kellaway was a pioneering clinical neurophysiologist and clinical investigator in the field of pediatric epilepsy. FIGURE Peter Kellaway Peter was born in Johannesburg, South Africa, the son of Cecil Kellaway, a stage and film actor, who was nominated twice for Academy Awards and won a Golden Globe award. As a child, Peter traveled extensively with his family, eventually settling in southern California. He attended Occidental College, earning bachelor and master degrees, and then moved to Montreal, Canada. There he worked with Herbert Jasper and received a doctorate degree in neurophysiology in 1947 from McGill University. In 1948, after a year on the faculty at McGill and the Montreal Neurologic Institute, Peter accepted a position at Baylor College of Medicine in Houston, first in the Department of Physiology and later in the Department of Neurology. He founded and served as Head of the Section of Neurophysiology until 1998. He …

Medical Thoracoscopic Talc Pleurodesis for Chylothorax Due to Lymphoma: A Case Series

Recurrent chylothorax as a complication of lymphoma has had unsatisfactory outcomes. Serial thoracentesis, tube thoracostomy, and pleurodesis via chest tube have been ineffective and compromise the nutritional and immune status of the patient. Medical thoracoscopic talc pleurodesis has been safe and effective in the treatment of some other varieties of recurrent pleural effusions. Our objective was to investigate the safety and efficacy of medical thoracoscopic talc pleurodesis in the palliation of chylothorax related to lymphoma. This is a report of 24 hemithoraces treated in 19 consecutive patients with lymphoma-related chylothorax, failing chemotherapy or radiation therapy. The average patient age was 55 years. Medical thoracoscopy was performed under local anesthesia and conscious sedation in a bronchoscopy suite. Sedation included midazolam (mean dose, 6 mg; range, 2-14 mg) with either meperidine (mean dose, 94 mg; range 25-140 mg), or morphine (mean dose, 18 mg; range 4-40 mg). Pleurodesis was performed with insufflation of sterile asbestos-free talc, (4-8 g). After pleurodesis, chest tubes were placed, with the mean duration of chest tube placement being 4 days, range 3 to 10 days. One patient died a few days after the procedure due to causes related to the primary disease process. Follow-up was for at least 90 days following the procedure. Patients were assessed at 30, 60, and 90 days following the procedure. At each of these endpoints, all patients remaining alive were without recurrence of pleural effusions, which was confirmed by chest radiography. Eight patients in the series died of the effects of their malignancy during the 90-day evaluation interval. Complications included medication reactions in two patients (8.3%) and ARDS in one patient (4.1%). Many patients with lymphoma-related chylothorax are refractory to chemotherapy and/or radiation therapy. In this group, medical thoracoscopic talc pleurodesis has an acceptable complication rate and a 100% success rate in the prevention of recurrence of pleural effusions at 30, 60, and 90 days following the procedure.

Hansen's disease following lymphoma

We report two instances of Hansen's disease as a complication of lymphoma. Although patients with leprosy may be at risk for the development of neoplasia, the converse has only rarely been reported. Nonetheless, granulomatous lesions in patients with lymphoreticular malignancy should suggest appropriate studies to rule out Hansen's disease, as illustrated by the cases detailed herein.

Haematological Complications of Lymphoma

Haematological Complications of Lymphoma

NEUROLOGIC MANIFESTATIONS AND COMPLICATIONS OF LYMPHOMA

NEUROLOGIC MANIFESTATIONS AND COMPLICATIONS OF LYMPHOMA

UREMIA DUE TO RENAL LYMPHOMATOSIS

Case Reports1 July 1960UREMIA DUE TO RENAL LYMPHOMATOSISALFRED W. WOLFSOHNALFRED W. WOLFSOHNSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-53-1-197 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptMalignant lymphoma, also known as lymphosarcoma, has never been proved to exist as a primary lesion in the kidney. Davis and Olivetti1 reported a case confined to the kidneys and the adrenal (chiefly cortex) and perirenal tissues, with one metastasis in the liver. They believed from the histologic characteristics that the lymphomatous process originated in the adrenal cortex and/or the periadrenal and perirenal adipose tissue. Since primary involvement of the kidney itself probably never occurs, Gibson2 has suggested that the term "lymphosarcoma of the kidney" be replaced by the more nearly correct designation, "renal lymphomatosis."The kidney is quite commonly...Bibliography1. DavisOlivetti FMRG: Primary lymphosarcomatosis of kidneys, adrenal glands, and perirenal adipose tissue, J. Urol. 66: 106-114 (July) 1951. CrossrefMedlineGoogle Scholar2. Gibson TE: Lymphosarcoma of the kidney, J. Urol. 60: 838-854 (Dec.) 1948. CrossrefMedlineGoogle Scholar3. WentzellBerkheiser RASW: Malignant lymphomatosis of the kidneys, J. Urol. 74: 177-185 (Aug.) 1955. CrossrefMedlineGoogle Scholar4. AbeshouseGoldstein BSAE: Metastatic malignant tumors of kidney: review of literature and report of 23 cases, Urol. and Cutan. Rev. 45: 163, 1941. Google Scholar5. Herbut PA: Urologic pathology, Vol. 1, 1952, Lea and Febiger, Philadelphia, pp. 636-640. Google Scholar6. Sägi T: Zu Uramie führende Nierenlymphosarkomatose, Ztschr. Urol. 50: 198-201, 1957. MedlineGoogle Scholar7. WallachScharfmanAngrist JBSBAA: Uremia due to replacement of renal parenchyma by tumor, J. Urol. 67: 623-628 (May) 1952. CrossrefMedlineGoogle Scholar8. Allen AC: The kidney, medical and surgical diseases, 1951, Grune and Stratton, New York, pp. 560-563, plates 318-325. Google Scholar9. WeisbergerPersky ASL: Renal calculi and uremia as complications of lymphomas, Am. J. M. Sc. 225: 669-673 (June) 1953. CrossrefMedlineGoogle Scholar10. JohnsonPeters MJCH: Lymphomas on four siblings, J. A. M. A. 163: 20-25 (Jan. 5) 1957. CrossrefMedlineGoogle Scholar11. Carter JR: Some basic concepts regarding tumors of lymphoid tissue, Am. J. Roentgenol. 76: 956-959 (Nov.) 1956. Google Scholar12. Osgood EE: A unifying concept of the etiology of the leukemias, lymphomas, and cancers, J. Nat. Cancer Inst. 18: 155-166 (Feb.) 1957. MedlineGoogle Scholar13. Gall EA: Hematopoietic neoplasms, in Schiff, L. (editor): Diseases of the liver, 1956, J. B. Lippincott Co., Philadelphia, pp. 554-555. Google Scholar14. Moore CV: Diseases of the reticuloendothelial system, in Cecil, R. L., and Loeb, R. F. (editors): A textbook of medicine, 9th Ed., 1955, W. B. Saunders Co., Philadelphia, p. 1163. Google Scholar15. HallOlson CAKB: Therapy of the malignant lymphomas. I. A study of 116 cases. II. A review, Am. J. Med. 20: 392-411 (Mar.) 1956. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: (MC) USNR Newport, Rhode Island*Received for publication January 5, 1959.From the Department of Medicine, U. S. Naval Hospital, Newport, Rhode Island.The opinions expressed are those of the author and do not necessarily reflect the views of the Department of the Navy.Requests for reprints should be addressed to Alfred W. Wolfsohn, M.D., 83 Morgan Street, Stamford, Connecticut. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPrimary renal lymphoma. Does it exist?Primary Renal Lymphoma Presenting as Acute Renal FailureAcute renal insufficiency due to lymphomatous infiltration of the kidneys.Report of six casesRenal Complications of LymphomaJOSEPH M. KIELY, M.D., F.A.C.P., RICHARD D. WAGONER, M.D., F.A.C.P., KEITH E. HOLLEY, M.D.Reticolosarcoma Renale E CalcolosiRenal Failure Incident to Reticulum Cell Sarcoma of the Kidneys Response to RadiotherapyDONALD ARMSTRONG, M.D., W. P. L. MYERS, M.D., F.A.C.P.Renal Involvement in Malignant Lymphomas: A Survey of 49 Cases 1 July 1960Volume 53, Issue 1Page: 197-203KeywordsAdipose tissueAdrenal cortexComaHospital medicineKidneysLesionsLiverLymphomaPrecursor cellsUrea Issue Published: 1 July 1960 PDF downloadLoading ...

Renal calculi as complications of leukemia and lymphomata.

Case Reports1 April 1959RENAL CALCULI AS COMPLICATIONS OF LEUKEMIA AND LYMPHOMATAIRVING FREEMAN, M.D., F.A.C.P., HERMAN MEISEL, M.D., F.A.C.S.IRVING FREEMAN, M.D., F.A.C.P.Search for more papers by this author, HERMAN MEISEL, M.D., F.A.C.S.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-50-4-1050 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIt has long been recognized that the serum uric acid may be elevated in a variety of diseases,1including gout, chronic nephritis, acute febrile diseases, pneumonia, sepsis, typhoid fever, erysipelas, scarlatina, tuberculosis, pernicious anemia immediately after onset of therapy, hemolytic anemias, polycythemia, diseases of the liver and biliary system, severe cardiac decompensation, diabetes mellitus (particularly with acidosis), leukemias6and lymphomata, chronic eczema, psoriasis and urticaria. A high fat diet and fasting also have been known to be associated with high uric acid levels. Excretion of uric acid roughly parallels the degree of elevation of this material in the blood, provided...Bibliography1. Brochner-Mortenson K: The uric acid content in blood and urine in health and disease, Medicine 19: 161-229 (May) 1940. CrossrefGoogle Scholar2. SandbergCartwrightWintrobe AAGEMM: Studies on leukemia. I. Uric acid excretion, Blood 11: 154-165 (Feb.) 1956. CrossrefMedlineGoogle Scholar3. WeisbergerPersky ASL: Renal calculi and uremia as complications of lymphoma, Am. J. M. Sc. 225: 669-673 (June) 1953. CrossrefMedlineGoogle Scholar4. OsgoodTiveyDavisonSeamanLi EEHKAJ: The relative rates of formation of new leukocytes in patients with acute and chronic leukemia, Cancer 5: 331-335 (Mar.) 1954. CrossrefGoogle Scholar5. RigasOsgood DAEE: In vivo life span of leukocytes of leukemic patients as measured by rate of incorporation of P & DNA fraction, Am. J. Med. 19: 292-293 (Aug.) 1955. CrossrefGoogle Scholar6. MerrillJackson DH: The renal complications of leukemia, New England J. Med. 228: 271-276, 1943. CrossrefGoogle Scholar7. KlineClifton DE: Lifespan of leucocytes in man, J. Appl. Physiol. 5: 79-84 (Aug.) 1952-53. CrossrefMedlineGoogle Scholar8. Merrill D: Uremia following x-ray therapy in leukemia, New England J. Med. 222: 94-97, 1940. CrossrefGoogle Scholar9. LearOppenheimer HG: Anuria following radiation therapy in leukemia, J. A. M. A. 143: 806-807, 1950. CrossrefMedlineGoogle Scholar10. KravitzDiamondCraver SCHL: Uremia complicating leukemia chemotherapy, J. A. M. A. 146: 1595-1597, 1951. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Fort Howard, Maryland*Received for publication August 6, 1957.From the Medical and Urological Services, Veterans Administration Hospital, Fort Howard, Maryland.Requests for reprints should be addressed to Irving Freeman, M.D., Veterans Administration Hospital, Fort Howard, Maryland. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byUric acid nephrolithiasisNiere bei Tumoren, Blutkrankheiten und ParaproteinämienRenal Failure Incident to Reticulum Cell Sarcoma of the Kidneys Response to RadiotherapyDONALD ARMSTRONG, M.D., W. P. L. MYERS, M.D., F.A.C.P. 1 April 1959Volume 50, Issue 4Page: 1050-1056KeywordsChronic liver diseaseHemoglobinLymphomaPneumoniaPolycythemiaPsoriasisSepsisTyphoidUric acidUrticaria ePublished: 1 December 2008 Issue Published: 1 April 1959 PDF downloadLoading ...